To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Allegra® Launched in JapanWorld's Second Largest Allergy Market Receives Widely Used Treatment Option
fastest growing prescription medicine for the safe and
effective treatment of seasonal allergy symptoms was
launched today in Japan, the second largest allergy
medication market in the world. Allegra®
(fexofenadine hydrochloride) was approved for use by
the Japanese Ministry of Health on September 22,
2000, and is now available by prescription only.
Allegra is a non-sedating antihistamine that has been shown in clinical trials and in clinical practice to safely provide relief from symptoms associated with seasonal allergies, in as little as one hour after dosing. Allegra was approved in Japan with recommended dosing of one 60 mg tablet, twice daily.
"Allegra has become one of the most widely used antihistamines in the world today, and will become an important new treatment option for millions of people in Japan who are seeking safe, non-sedating relief from disruptive and uncomfortable allergy symptoms," said Richard Markham, Chief Executive Officer of Aventis Pharma, the company that discovered, developed and markets Allegra.
Reports estimate that as much as USD $1. billion (source: IMS, MAT August 2000) is spent each year in Japan on allergy medications. It is also estimated that Japan represents 20% of the overall global allergy market, and is second only to the United States in the use of antihistamine treatments.
"We believe the Japanese market represents a considerable opportunity for Allegra and we are pleased that allergy sufferers there now have this option," said Mr. Markham.
Allegra is currently available in 50 countries worldwide and is backed by more than 1.5 billion patient days of experience. Allegra was first approved for use in the United States in July of 1996 and is considered the 7th most successful new product launched in the past five years (source: IMS, 1999).
Clinical Data In clinical trials of Allegra, the onset of action of the drug was observed within one hour after dosing. Additional studies have shown that allergy sufferers continued feeling relief throughout the dosing period. Also, Allegra was shown to relieve symptoms among allergy sufferers in a study in which those sufferers were exposed for five hours to extremely high pollen challenges in a pollen chamber. This exposure is typically much greater than what most patients would experience in "very high" pollen season.
Other clinical trials have demonstrated that Allegra provides effective symptom relief without sedating side effects or impairment of performance. Consequently, unlike other antihistamines in Japan, such as Zyrtec
- 1Scientists get first glimpse of a chemical bond being born
- 2Penta-graphene, a new structural variant of carbon, discovered
- 3Novozymes, Cargill continue bio-acrylic acid partnership as BASF exits
- 4Bio-succinic Acid Wins Biofuels Digest Chemical Of The Year Award
- 5WACKER Closes 2014 Ahead of Expectations
- 6Better batteries inspired by lowly snail shells
- 7Scientists set quantum speed limit
- 8Breakthrough may lead to industrial production of graphene devices
- 9Evidence mounts for quantum criticality theory
- 10BASF starts Open Innovation contest on energy storage
- Oxea Announces Price Increase for Specialty Esters
- Dr. Richard Pott to be Chairman of the Supervisory Board of Bayer MaterialSc ...
- Bayer: All subgroups contribute to record sales and earnings
- Warming up the world of superconductors
- Ralph R. Dammel from Merck receives the Frits Zernike Award for Microlithography